Back to results
US 2022/0031777 A1Published application
Methods of Treating Cancer
AssigneeKaliVir Immunotherapeutics, Inc.
InventorStephen H. THORNE
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.
Claims42
A method of treating a tumor in a subject, comprising:
- administering to the subject a first recombinant microorganism,
- wherein the first recombinant microorganism replicates in a tumor cell and does not replicate in a non-tumor cell or displays attenuated replication in a non-tumor cell, and
- wherein the first recombinant microorganism is a virus or a bacterium;
- administering to the subject a second recombinant microorganism,
- wherein the second recombinant microorganism replicates in a tumor cell and does not replicate in a non-tumor cell or displays attenuated replication in a non-tumor cell, and
- wherein the second recombinant microorganism is a virus;
- and
- enhancing or eliciting an immune response to a protein expressed by a tumor associated cell that is not coded for or expressed by the first recombinant microorganism and the second recombinant microorganism.
5 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
17-33. (canceled)
(canceled)
(canceled)
39-100. (canceled)
(canceled)
(canceled)
105-153. (canceled)
(canceled)
162-166. (canceled)
(canceled)
170-183. (canceled)
A method of treatment, comprising:
- administering to a subject a first recombinant microorganism,
- wherein the first recombinant microorganism comprises an exogenous nucleic acid encoding a cytokine receptor,
- wherein the first recombinant microorganism replicates in a tumor microenvironment, and
- wherein the first recombinant microorganism is a virus or a bacterium;
- administering to the subject a second recombinant microorganism,
- wherein the second recombinant microorganism comprises an exogenous nucleic acid encoding a cytokine receptor,
- wherein the second recombinant microorganism replicates in a tumor microenvironment, and
- wherein the second recombinant microorganism is an oncolytic virus;
- and
- enhancing or eliciting an immune response to a protein expressed by a non-tumorous cell present within the tumor microenvironment that is not coded for or expressed by the first recombinant microorganism and the second recombinant microorganism.
7 more elements
Dependencies are inferred from the claim text.